OncoCyte Corporation (OCX): Price and Financial Metrics


OncoCyte Corporation (OCX): $0.98

-0.10 (-8.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

OCX POWR Grades


  • Growth is the dimension where OCX ranks best; there it ranks ahead of 20.17% of US stocks.
  • The strongest trend for OCX is in Momentum, which has been heading down over the past 179 days.
  • OCX ranks lowest in Quality; there it ranks in the 1st percentile.

OCX Stock Summary

  • As for revenue growth, note that OCX's revenue has grown 535.44% over the past 12 months; that beats the revenue growth of 98.25% of US companies in our set.
  • The volatility of Oncocyte Corp's share price is greater than that of 95.51% US stocks with at least 200 days of trading history.
  • Oncocyte Corp's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -58.46%, greater than the shareholder yield of only 7.56% of stocks in our set.
  • Stocks that are quantitatively similar to OCX, based on their financial statements, market capitalization, and price volatility, are ASTC, AVLR, ASXC, AMST, and GAN.
  • Visit OCX's SEC page to see the company's official filings. To visit the company's web site, go to www.oncocyte.com.

OCX Valuation Summary

  • OCX's EV/EBIT ratio is -9; this is 130.72% lower than that of the median Healthcare stock.
  • Over the past 69 months, OCX's EV/EBIT ratio has gone up 24.3.
  • OCX's price/sales ratio has moved NA NA over the prior 69 months.

Below are key valuation metrics over time for OCX.

Stock Date P/S P/B P/E EV/EBIT
OCX 2021-08-31 89.2 3.7 -13.7 -9.0
OCX 2021-08-30 88.1 3.6 -13.5 -8.8
OCX 2021-08-27 91.3 3.7 -14.0 -9.2
OCX 2021-08-26 87.2 3.6 -13.4 -8.7
OCX 2021-08-25 89.2 3.7 -13.7 -9.0
OCX 2021-08-24 89.8 3.7 -13.8 -9.0

OCX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OCX has a Quality Grade of F, ranking ahead of 0.09% of graded US stocks.
  • OCX's asset turnover comes in at 0.04 -- ranking 335th of 681 Pharmaceutical Products stocks.
  • ITCI, BHVN, and LFVN are the stocks whose asset turnover ratios are most correlated with OCX.

The table below shows OCX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.040 -0.136 -2.643
2021-03-31 0.030 -0.173 -1.674
2020-12-31 0.021 -0.525 -1.429
2020-09-30 0.013 -0.595 -1.555
2020-06-30 0.003 -2.384 -1.709
2020-03-31 0.000 -9.812 -2.256

OCX Price Target

For more insight on analysts targets of OCX, see our OCX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.67 Average Broker Recommendation 1.4 (Strong Buy)

OCX Stock Price Chart Interactive Chart >

Price chart for OCX

OCX Price/Volume Stats

Current price $0.98 52-week high $6.25
Prev. close $1.08 52-week low $0.97
Day low $0.97 Volume 802,900
Day high $1.05 Avg. volume 487,798
50-day MA $1.26 Dividend yield N/A
200-day MA $2.39 Market Cap 98.37M

OncoCyte Corporation (OCX) Company Bio


OncoCyte Corporation focuses on developing diagnostic tests for the detection of breast, bladder, and lung cancers. The company was founded in 2009 and is based in Alameda, California.


OCX Latest News Stream


Event/Time News Detail
Loading, please wait...

OCX Latest Social Stream


Loading social stream, please wait...

View Full OCX Social Stream

Latest OCX News From Around the Web

Below are the latest news stories about Oncocyte Corp that investors may wish to consider to help them evaluate OCX as an investment opportunity.

Shareholders in OncoCyte (NASDAQ:OCX) have lost 78%, as stock drops 12% this past week

The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...

Yahoo | February 21, 2022

Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

IRVINE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that management will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Presentation Details: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Fireside Chat

Yahoo | February 10, 2022

BTIG Thinks OncoCyte’s Stock is Going to Recover

BTIG analyst Mark Massaro reiterated a Buy rating on OncoCyte (OCX – Research Report) yesterday and set a price target of $5.00. The company's shares closed last Wednesday at $1.66, close to its 52-week low of $1.65. According to TipRanks.com, Massaro is a 5-star analyst with an average return of 11.2% and a 51.0% success rate. Massaro covers the Healthcare sector, focusing on stocks such as MDxHealth S.A. Sponsored ADR, Ginkgo Bioworks Holdings, and Lucid Diagnostics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for OncoCyte with a $4.05 average price target, which is a 90.1% upside from current levels.

Howard Kim on TipRanks | January 20, 2022

Needham Thinks OncoCyte’s Stock is Going to Recover

Needham analyst Michael Matson maintained a Buy rating on OncoCyte (OCX – Research Report) today and set a price target of $5.00. The company's shares closed last Tuesday at $2.19, close to its 52-week low of $1.80. According to TipRanks.com, Matson is a 4-star analyst with an average return of 8.7% and a 53.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings. The word on The Street in general, suggests a Strong Buy analyst consensus rating for OncoCyte with a $4.05 average price target, which is a 105.6% upside from current levels.

Howard Kim on TipRanks | January 19, 2022

Following agreement with Thermo Fisher, Oncocyte shares plunge 24%

Following an after-the-closing bell announcement yesterday of a development and co-marketing agreement with Thermo Fisher Scientific, shares of Oncocyte fell sharply today.

Seeking Alpha | January 19, 2022

Read More 'OCX' Stories Here

OCX Price Returns

1-mo -13.27%
3-mo -32.41%
6-mo -59.34%
1-year -77.42%
3-year -78.13%
5-year -81.51%
YTD -54.84%
2021 -9.21%
2020 6.22%
2019 63.04%
2018 -70.32%
2017 -34.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7209 seconds.